Retail Rollout Progress

It has been over a week since Japan officially authorized the over-the-counter (OTC) sale of NorLevo, an emergency contraceptive marketed by Daiichi Sankyo Healthcare. As of mid-February, the medication remains available at approximately 5,400 pharmacies, priced at ¥7,480 per dose.

The program aims to bridge the gap for those unable to visit a clinic within the critical 72-hour window following unprotected intercourse, where the drug maintains roughly 80% effectiveness in preventing pregnancy.

The Pharmacist’s Role

Unlike standard OTC medications, the morning-after pill requires a mandatory consultation. Purchasers must take the pill on-site in the presence of a trained pharmacist. This regulation ensures patients receive accurate information regarding potential side effects and future contraceptive planning.

Major chains like Welcia Pharmacy have reported that nearly all of their 7,200 pharmacists have completed the specialized training required by the health ministry to handle these sensitive consultations.

Privacy & Support Measures

To address concerns regarding social stigma, pharmacies have implemented “point-and-check” sheets and numerical coding systems so that customers do not have to announce the medication name out loud. Consultations are conducted at partitioned counters to ensure maximum privacy.

Crucially, pharmacists are now part of a coordinated network with local obstetricians. If a customer is suspected of having experienced sexual violence, pharmacies are equipped to provide immediate referrals to medical professionals and specialized support centers.

Ongoing Accessibility Challenges

While health experts like Dr. Ruriko Tsushima describe the move as long overdue, advocacy groups like Pilcon continue to lobby for further improvements. Primary concerns include the high out-of-pocket cost and the lack of 24-hour availability in rural areas where dispensing pharmacies may not have trained staff on night shifts.

As the pilot continues through 2026, the health ministry is expected to monitor sales data and patient feedback to determine if the program should be expanded to include more locations and more affordable pricing tiers.